120 related articles for article (PubMed ID: 8562956)
1. Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations.
Knecht H; Raphaël M; McQuain C; Rothenberger S; Pihan G; Camilleri-Broët S; Bachmann E; Kershaw GR; Ryan S; Kittler EL; Quesenberry PJ; Schlaifer D; Woda BA; Brousset P
Blood; 1996 Feb; 87(3):876-81. PubMed ID: 8562956
[TBL] [Abstract][Full Text] [Related]
2. Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations.
Berger C; Brousset P; McQuain C; Knecht H
Leuk Lymphoma; 1997 Jul; 26(3-4):239-50. PubMed ID: 9322886
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
4. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas.
Camilleri-Broët S; Davi F; Feuillard J; Bourgeois C; Seilhean D; Hauw JJ; Raphaël M
Blood; 1995 Jul; 86(2):432-5. PubMed ID: 7605982
[TBL] [Abstract][Full Text] [Related]
5. High frequency of a 30-bp deletion of Epstein-Barr virus latent membrane protein 1 gene in primary HIV non-Hodgkin's brain lymphomas.
Vallat-Decouvelaere AV; Bretel MA; Vassias I; Laplanche JL; Polivka M; Wassef M; Brunet M; Thiebaut JB; Gosselin B; Morinet F; Mikol J
Neuropathol Appl Neurobiol; 2002 Dec; 28(6):471-9. PubMed ID: 12445163
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of latent membrane protein 1 in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
Tabata YHibi S; Teramura T; Kuriyama K; Yagi T; Todo S; Sawada T; Imashuku S
Leuk Lymphoma; 2000 Jul; 38(3-4):373-80. PubMed ID: 10830744
[TBL] [Abstract][Full Text] [Related]
7. Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-kappaB-mediated transcription.
Rothenberger S; Bachmann E; Berger C; McQuain C; Odermatt BF; Knecht H
Oncogene; 1997 May; 14(17):2123-6. PubMed ID: 9160892
[TBL] [Abstract][Full Text] [Related]
8. Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV-associated reactive and malignant lympho-proliferations.
Berger C; Rothenberger S; Bachmann E; McQuain C; Nadal D; Knecht H
Int J Cancer; 1999 May; 81(3):371-5. PubMed ID: 10209951
[TBL] [Abstract][Full Text] [Related]
9. A deletion mutant of the LMP1 oncogene of Epstein-Barr virus is associated with evolution of angioimmunoblastic lymphadenopathy into B immunoblastic lymphoma.
Knecht H; Martius F; Bachmann E; Hoffman T; Zimmermann DR; Rothenberger S; Sandvej K; Wegmann W; Hurwitz N; Odermatt BF
Leukemia; 1995 Mar; 9(3):458-65. PubMed ID: 7885044
[TBL] [Abstract][Full Text] [Related]
10. [Functional analysis of Epstein-Barr virus latent membrane proteins (LMP1) in patients with limphoproliferative disorders].
Smirnova KV; Diduk SV; Gurtsevich VÉ
Biomed Khim; 2011; 57(1):114-26. PubMed ID: 21516783
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.
Liebowitz D
N Engl J Med; 1998 May; 338(20):1413-21. PubMed ID: 9580648
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of different LMP1 proteins isolated from Epstein-Barr virus-positive carriers.
Fischer N; Kopper B; Graf N; Schlehofer JR; Grässer FA; Mueller-Lantzsch N
Virus Res; 1999 Mar; 60(1):41-54. PubMed ID: 10225273
[TBL] [Abstract][Full Text] [Related]
13. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders.
Knecht H; Bachmann E; Brousset P; Rothenberger S; Einsele H; Lestou VS; Delsol G; Bachmann F; Ambros PF; Odermatt BF
Oncogene; 1995 Feb; 10(3):523-8. PubMed ID: 7845677
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain.
Huen DS; Henderson SA; Croom-Carter D; Rowe M
Oncogene; 1995 Feb; 10(3):549-60. PubMed ID: 7845680
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8.
Horenstein MG; Nador RG; Chadburn A; Hyjek EM; Inghirami G; Knowles DM; Cesarman E
Blood; 1997 Aug; 90(3):1186-91. PubMed ID: 9242551
[TBL] [Abstract][Full Text] [Related]
16. Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma.
Mehl AM; Fischer N; Rowe M; Hartmann F; Daus H; Trümper L; Pfreundschuh M; Müller-Lantzsch N; Grässer FA
Int J Cancer; 1998 Apr; 76(2):194-200. PubMed ID: 9537580
[TBL] [Abstract][Full Text] [Related]
17. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells.
Pai S; O'Sullivan BJ; Cooper L; Thomas R; Khanna R
J Virol; 2002 Feb; 76(4):1914-21. PubMed ID: 11799186
[TBL] [Abstract][Full Text] [Related]
18. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.
Brink AA; Dukers DF; van den Brule AJ; Oudejans JJ; Middeldorp JM; Meijer CJ; Jiwa M
J Clin Pathol; 1997 Nov; 50(11):911-8. PubMed ID: 9462239
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.
Kaye KM; Devergne O; Harada JN; Izumi KM; Yalamanchili R; Kieff E; Mosialos G
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):11085-90. PubMed ID: 8855313
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
